The estimated Net Worth of Sherilyn S Mc Coy is at least $486 Thousand dollars as of 4 May 2023. Ms. Coy owns over 841 units of NovoCure Ltd stock worth over $77,707 and over the last 17 years she sold NVCR stock worth over $0. In addition, she makes $408,526 as Independent Director at NovoCure Ltd.
Sherilyn has made over 8 trades of the NovoCure Ltd stock since 2011, according to the Form 4 filled with the SEC. Most recently she exercised 841 units of NVCR stock worth $14,490 on 4 May 2023.
The largest trade she's ever made was exercising 40,000 units of NovoCure Ltd stock on 23 April 2017 worth over $689,200. On average, Sherilyn trades about 5,339 units every 97 days since 2008. As of 4 May 2023 she still owns at least 4,510 units of NovoCure Ltd stock.
You can see the complete history of Ms. Coy stock trades at the bottom of the page.
Sherilyn S. McCoy serves as Independent Director of the Company. From 2012 to 2018, Ms. McCoy was the chief executive officer of Avon Products, Inc., a direct selling company in beauty, household, and personal care categories. Prior to joining Avon, Ms. McCoy had various roles at Johnson & Johnson, a multinational medical devices, pharmaceutical and consumer packaged goods manufacturing company. During her distinguished 30-year career at Johnson & Johnson, she served, most recently as vice chairman of the executive committee and member of the office of the chairman, where she was responsible for the pharmaceutical and consumer business divisions of the company. She was appointed as the Vice Chairman in January 2011. Ms. McCoy holds four U.S. patents and she has been on Fortune magazine’s “50 Most Powerful Women in Business", a list on which she has been included since 2008. In August 2012, she was recognized as the 39th most powerful woman in the world by Forbes Magazine. She has been Director of AstraZeneca PLC since 2017; director of Stryker Corporation since 2018, and director of Kimberly-Clark Corporation since 2018. Formerly a director of Avon Products, Inc. from 2012 to 2018. She holds B.A. in textile chemistry, University of Massachusetts, Dartmouth; Masters in chemical engineering, Princeton University; MBA, Rutgers University.
As the Independent Director of NovoCure Ltd, the total compensation of Sherilyn McCoy at NovoCure Ltd is $408,526. There are 14 executives at NovoCure Ltd getting paid more, with William Doyle having the highest compensation of $8,286,100.
Sherilyn McCoy is 61, she's been the Independent Director of NovoCure Ltd since 2018. There are 8 older and 16 younger executives at NovoCure Ltd. The oldest executive at NovoCure Ltd is Prof. Yoram Palti, 83, who is the Founder & CTO.
Sherilyn's mailing address filed with the SEC is 1941 STRYKER WAY, , PORTAGE, MI, 49002.
Over the last 9 years, insiders at NovoCure Ltd have traded over $237,132,855 worth of NovoCure Ltd stock and bought 164,174 units worth $2,198,429 . The most active insiders traders include Asaf Danziger, William Fwfd Ventures Fund ..., and Michael J. Ambrogi. On average, NovoCure Ltd executives and independent directors trade stock every 7 days with the average trade being worth of $853,350. The most recent stock trade was executed by Ashley Cordova on 2 August 2024, trading 688 units of NVCR stock currently worth $13,856.
we are a commercial-stage oncology company developing a novel, proprietary therapy called tumor treating fields, or ttfields, for the treatment of solid tumor cancers. we count on the contributions of our talented team members who are committed to improving the lives of cancer patients. here at novocure, cancer patients and their families are – and have always been – at the core of our mission. we expect our colleagues to excel, and in return, we invest in their professional growth and personal well-being. we seek high performers who thrive in fast-paced environments and are inspired by making a difference in cancer care. we offer employment opportunities in the u.s., europe and asia.
NovoCure Ltd executives and other stock owners filed with the SEC include: